Table 4.
AMR profiles (ETESTs) for Flagstaff isolates. Units are in microgram/milliliter (μg/ml)
|
Antimicrobial |
Antimicrobial class |
ES-W-0016-02 (C-III) |
ES-S-0010-02 (C-III) |
ES-S-0173-01 (C-III) |
ES-S-0054-01 (C-IV) |
Replicate |
R breakpoint |
S breakpoint |
Reference |
|---|---|---|---|---|---|---|---|---|---|
|
Ceftriaxone (CRO) |
Cephalosporin |
32 |
48 |
48 |
12 |
Rep1 |
≥64 |
≤16 |
CLSI 2020 |
|
32 |
48 |
48 |
12 |
Rep2 |
|
|
|
||
|
Ceftazidime (CAZ) |
Cephalosporin |
>256 |
>256 |
24 |
32 |
Rep1 |
≥64 |
≤16 |
CLSI 2020 |
|
>256 |
>256 |
24 |
32 |
Rep2 |
|
|
|
||
|
Cefotaxime (CXT) |
Cephalosporin |
>32 |
>32 |
>32 |
>32 |
Rep1 |
≥64 |
≤16 |
CLSI 2020 |
|
>32 |
>32 |
>32 |
>32 |
Rep2 |
|
|
|
||
|
Cefepime (FEP) |
Cephalosporin |
>256 |
>256 |
>256 |
>256 |
Rep1 |
≥16 |
≤2 |
CLSI 2020* |
|
>256 |
>256 |
>256 |
>256 |
Rep2 |
|
|
|
||
|
Clindamycin (CLI) |
Macrolide |
8 |
12 |
2 |
16 |
Rep1 |
≥8 |
≤2 |
CLSI 2020 |
|
8 |
12 |
2 |
16 |
Rep2 |
|
|
|
||
|
Erythromycin (ERY) |
Macrolide |
1 |
1 |
1 |
0.25 |
Rep1 |
≥8 |
≤2 |
EUCAST 2014 |
|
1 |
1 |
1 |
0.25 |
Rep2 |
|
|
|
||
|
Imipenem (IMP) |
Carbapenem |
8 |
6 |
6 |
4 |
Rep1 |
≥16 |
≤4 |
CLSI 2014 |
|
8 |
6 |
6 |
4 |
Rep2 |
|
|
|
||
|
Ciprofloxacin (CIP) |
Fluoroquinolone |
16 |
>32 |
>32 |
>32 |
Rep1 |
≥8 |
≤2 |
CLSI 2020† |
|
16 |
>32 |
>32 |
>32 |
Rep2 |
|
|
|
||
|
Moxifloxacin (MXF) |
Fluoroquinolone |
1.5 |
1.5 |
1.5 |
2 |
Rep1 |
≥8 |
≤2 |
CLSI 2020 |
|
1.5 |
1.5 |
1.5 |
2 |
Rep2 |
|
|
|
||
|
Levofloxacin (LVX) |
Fluoroquinolone |
8 |
8 |
8 |
16 |
Rep1 |
≥2 |
≤0.5 |
CLSI 2020* |
|
8 |
8 |
8 |
16 |
Rep2 |
|
|
|
||
|
Susceptible |
|
||||||||
|
Intermediate |
|
||||||||
|
Resistant |
|
*Breakpoint for Enterobacteriaceae used.
†Breakpoint for moxifloxacin used.
EUCAST, European Committee on Antimicrobial Susceptibility Testing.